Showing results (121-130 of 264) with videos related to
Sort By:
Pageof 27
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Inhibition of human and pig ureter motility in vitro and in vivo by the K(+) channel openers PKF 217-744b and nicorandilRuth Weiss, Meike Mevissen, Daniela S Hauser, et al.European Urology|July 15, 2010
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic reviewPaul C M S Verhagen, Fritz H Schröder, Laurence Collette, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trialsJulien Péron, Anouk Neven, Laurence Collette, et al.European Urology|March 20, 2009
Pelvic lymph node dissection in prostate cancerAlberto Briganti, Michael L Blute, James H Eastham, et al.Radiology|June 4, 2014
Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imagingHarriet C Thoeny, Johannes M Froehlich, Maria Triantafyllou, et al.European Urology|September 24, 2011
Lymph node dissection in renal cell carcinomaUmberto Capitanio, Frank Becker, Michael L Blute, et al.Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|March 4, 2011
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001)Andrea Wittig, Sien-Yi Sheu-Grabellus, Laurence Collette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca PharmaceuticalsLaurence Collette, Tomasz Burzykowski, Kevin J Carroll, et al.The Journal of Urology|August 18, 2004
Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955Marco Bisoffi, Irena Klima, Ekaterina Gresko, et al.European Urology|October 24, 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksHendrik Isbarn, Laurent Boccon-Gibod, Peter R Carroll, et al.Pageof 27